

Vaccine Info**

Infection Info**

Product information:

- Recombivax HB by MFC (HBV)
www.merck.ca/assets/en/pdf/products/RECOMBIVAX_HB-09_03-a_126922_E.pdf
- Engerix-B by GSK (HBV)
www.gsk.ca/english/docs-pdf/Engerix%20B_PM_20080923_EN.pdf
- Infanrix-HEXA by GSK (DtaP- HBV-IPV-HIB)
www.gsk.ca/english/docs-pdf/Infanrix-hexa_PM_20080718_EN.pdf
- Twinrix by GSK (HAV and HBV)
www.gsk.ca/english/docs-pdf/Twinrix_PM_20080916_EN.pdf

Compliance: 60% of Canadian children by 17 years of age in 2004

Efficacy: 90-99% in people who are healthy and young

Type: inactivated virus or viral subunit vaccine administered by injection

Age of first dose: infancy, preteen or teen

Year introduced: early 1990's implemented a national program targeted children 9-13 years in Canada

Type: A viral infection of the liver that is usually self-limiting in adults. Infants and children have a much higher risk of developing a chronic liver infection.

Symptoms: Yellowish skin and abdominal pain. Unborn and newborn babies are at higher risk of complications.

Treatments: No treatments are available.

Exposure: Transferred through contact with blood or body fluids (sexual contact, sharing needles, blood transfusion).

Risk: Children whose mothers are Hep B positive, children who are in a child care setting with a Hep B positive child, staff and inmates at correctional facilities and people who travel to high risk areas are at a higher risk.

Incidence: 2.7 cases per 100,000 Canadians in 2004. In 2004, 4 cases in children under 1 year, 3 cases in children 1-4yrs, 1 case in children 5-9 years, 1 case in children 10-14 years.

Deaths: 1-2% of cases of acute infections result in death. From 2000-2006, 0 deaths due to hepatitis B were recorded in people aged 0-19 in Canada.